ARDELYX, INC. (ARDX) research
ARDELYX, INC.- Sector
- Biotechnology
- Last price
- $3.39
- As of
Kresmion compiles this page from ARDX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ARDELYX, INC. (ARDX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-17.
As of . Source: SEC EDGAR filings for ARDX. Method and limitations.
Share the ARDX intelligence card
See the full ARDX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ARDX on one page. Preview it with sample data, then open it live with a free account.
Preview the ARDX dossierActive signals for ARDX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 7.0%, EPS $-0.07 vs $-0.0654 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 63% of ARDX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +344% to ARDX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 100% of ARDX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 98% of ARDX (2026Q2)
FREE, NO ACCOUNT
Every signal on ARDX, as it fires
You are seeing 5 of 13 signals recorded on ARDX since 2026-06-10.
The five above all landed on 2026-08-16. The other 8 were recorded on 2 other days. 9 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ARDX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 039697107 · 2026Q2 | $70.9M | 0.03% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 039697107 · 2026Q2 | $26.6M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 039697107 · 2026Q2 | $5.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 039697107 · 2026Q2 | $4.6M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 039697107 · 2026Q2 | $67K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ARDX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ARDX against its peers
ARDX's operating margin of -10.1% ranks in the 72nd percentile of 8 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ARDX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 407M USD | 49.8M USD | 95 | 9 |
| Operating margin | -10.1% | -184.6% | 72 | 8 |
| Net margin | -15.1% | -169.5% | 72 | 8 |
| Return on equity | -36.9% | -43.7% | 64 | 17 |
Peers (18): TBPH, ABUS, RIGL, JBIO, GLUE, SANA, SGP, KURA, CGEM, LXRX, CRVS, AVTX, ACHV, ANNX, MLTX, DSGN, GERN, JANX. Left out: IVA (period gap), APMD (no annual filing), HELP (period gap), OBX (no annual filing), ATTO (no annual filing), ANL (period gap), SPTX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ARDX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ARDX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ARDX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.